Largest Hospital in Europe Expands Access to Precise
Radiation Treatments to More Patients
SUNNYVALE, California,
March 15, 2019 /PRNewswire/
-- Europe's largest hospital with 3,700 beds1,
Bilkent City Hospital located in Ankara, selected Accuray Incorporated's
(NASDAQ: ARAY) next-generation TomoTherapy® platform,
the Radixact® System, to expand access to precise
radiation treatments to more patients. It is the first Radixact
System to be included in a Ministry of Health and Public Private
Partnership City Hospital and the second system of its kind in
Turkey. The advanced radiotherapy
system will enable the Bilkent clinical team to treat virtually any
case for which radiation therapy is prescribed, including not only
standard indications such as breast and head and neck cancers but
also complex treatments such as total marrow irradiation.
Turkey's President, Recep
Tayyip Erdoğan, along with other government officials, attended
Bilkent's opening ceremony on
March 14, 2019 in support of the
hospital's commitment to providing Turkish citizens with world
class medical care. The hospital is dedicated to delivering the
best treatment possible, regardless of a person's economic
status.
"Turkey, through facilities
such as the Bilkent City Hospital, is embarking on a strategy to
truly change the way that its citizens with cancer are treated,"
said Birgit Fleurent, Chief
Marketing Officer at Accuray. "We are proud that the Bilkent
Hospital team chose the Radixact System to help them make access to
potentially life-saving radiation treatments a reality for more
patients. We believe the system provides the versatility and
efficiency needed to enable the clinical team to keep pace with the
expected demands of a busy hospital, and will allow them to deliver
precise radiation to almost any tumor in the shortest amount of
time possible."
The Radixact System offers benefits to patients and the
clinicians who treat them
- The Radixact System is fully integrated with the Accuray
Precision® Treatment Planning System (TPS) and
iDMS® Data Management System. Together, these radiation
therapy solutions are designed to improve treatment outcomes and
workflow efficiencies, enabling clinicians to provide optimal
treatments for more patients, every day
- The Radixact System offers clinicians the flexibility to
deliver treatment from clinician-specified beam angles with
TomoDirect™ mode, or by continuous delivery of radiation from 360
degrees around the patient using TomoHelical™ mode, resulting in
highly accurate, individualized dose distributions that more
precisely conform to the shape of the patient's tumor
- PreciseART® Adaptive Radiation Therapy Software
makes adaptive radiotherapy simple and practical for every
practice. This software enables clinicians to monitor every patient
and efficiently adapt plans, helping them to deliver more precise
treatments to more patients
- The PreciseRTX® Retreatment Option accelerates and
automates the re-planning process to make re-treatment more
efficient for practices and more effective for patients in those
cases where, unfortunately, cancer has recurred and additional
radiation treatments are necessary
The Bilkent City Hospital in Ankara was built through a Public Private
Partnership and will be one of the Turkish Ministry of Health
reference sites. Constructed by CCN Construction and managed by CCN
Holding, its campus consists of six hospitals, including an
oncology hospital. Bilkent Hospital is the largest hospital in
Europe, with 3,700 beds. MEDITEL
Healthcare, as the exclusive distributor, installer and training
partner for the Accuray's TomoTherapy Radixact platform in
Turkey, worked with the Bilkent
Hospital team as they evaluated radiotherapy systems and selected
the Radixact System.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that make cancer treatments shorter,
safer, personalized and more effective, ultimately enabling
patients to live longer, better lives. The company's radiation
treatment delivery systems in combination with fully-integrated
software solutions set the industry standard for precision and
cover the full range of radiation therapy and radiosurgery
procedures. For more information, please visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences, patient outcomes and the
company's ability to continue to penetrate the global radiation
therapy market. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products,
including new product offerings, the company's ability to develop
new products or enhance existing products to meet customers' needs,
delays in the development or release of new offerings and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the SEC on
February 8, 2019, and as updated
periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts:
|
Beth
Kaplan
|
Jayme
Maniatis
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-6610
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
_____________________________
1
https://health.gov.tr/EN,40108/official-launch-of-the-bilkent-city-hospital-by-the-undersecretary-prof-dr-eyup-gumus.html.
Accessed on March 12, 2019
Logo -
https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg